{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:26:21Z","timestamp":1774362381741,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Minufiya University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasitol Res"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite being the initial choice for treating toxoplasmosis, sulfadiazine and pyrimethamine have limited effectiveness in eliminating the infection and were linked to a variety of adverse effects. Therefore, the search for new effective therapeutic strategies against toxoplasmosis is still required. The current work is the first research to assess the efficacy of spiramycin-loaded maltodextrin nanoparticles (SPM-loaded MNPs) as a novel alternative drug therapy against toxoplasmosis in a murine model. Fifty laboratory-bred Swiss albino mice were divided into five groups: normal control group (GI, <jats:italic>n<\/jats:italic>\u2009=\u200910), positive control group (GII, <jats:italic>n<\/jats:italic>\u2009=\u200910), orally treated with spiramycin (SPM) alone (GIII, <jats:italic>n<\/jats:italic>\u2009=\u200910), intranasal treated with SPM-loaded MNPs (GIV, <jats:italic>n<\/jats:italic>\u2009=\u200910), and orally treated with SPM-loaded MNPs (GV, <jats:italic>n<\/jats:italic>\u2009=\u200910). Cysts of\u00a0<jats:italic>Toxoplasma gondii\u00a0<\/jats:italic>ME-49 strain were used to infect the mice. Tested drugs were administered 2\u00a0months after the infection. Drug efficacy was assessed by counting brain cysts, histopathological examination, and measures of serum CD19 by flow cytometer. The orally treated group with SPM-loaded MNPs (GV) showed a marked reduction of brain cyst count (88.7%), histopathological improvement changes, and an increasing mean level of CD19 (80.2%) with significant differences. SPM-loaded MNPs showed potent therapeutic effects against chronic toxoplasmosis. Further research should be conducted to assess it in the treatment of human toxoplasmosis, especially during pregnancy.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s00436-024-08280-4","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T08:02:56Z","timestamp":1721808176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Spiramycin-loaded maltodextrin nanoparticles as a promising treatment of toxoplasmosis on murine model"],"prefix":"10.1007","volume":"123","author":[{"given":"Ayman A.","family":"Abdel-Wahab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia A.","family":"Shafey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar M.","family":"Selim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraya A.","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0572-1855","authenticated-orcid":false,"given":"Khloud K.","family":"Mohsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina M.","family":"Allam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally W.","family":"Elkhadry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa A.","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"8280_CR1","doi-asserted-by":"publisher","unstructured":"Abdallah K, Saleh M, Kishk S, Barakat A, Ali B, elkholy A (2022) A new approach in treatment of chronic murine models of toxoplasmosis using nitrofurantoin antibiotic. ZUMJ 1169\u20131175. https:\/\/doi.org\/10.21608\/zumj.2022.112316.2440","DOI":"10.21608\/zumj.2022.112316.2440"},{"issue":"288","key":"8280_CR2","doi-asserted-by":"publisher","first-page":"119378","DOI":"10.1016\/j.carbpol.2022.119378","volume":"15","author":"SM Abdel-Hafez","year":"2022","unstructured":"Abdel-Hafez SM, Zapp J, Gallei M, Schneider M (2022) Formulation attributes, acid tunable degradability and cellular interaction of acetalated maltodextrin nanoparticles. Carbohydr Polym 15(288):119378. https:\/\/doi.org\/10.1016\/j.carbpol.2022.119378","journal-title":"Carbohydr Polym"},{"issue":"1","key":"8280_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12639-021-01431-9","volume":"46","author":"AF Allam","year":"2022","unstructured":"Allam AF, Hagras NA, Farag HF, Osman MM, Shalaby TI, Kazem AH, Shehab AY, Mogahed NM (2022) Remarkable histopathological improvement of experimental toxoplasmosis after receiving spiramycin-chitosan nanoparticles formulation. J Parasit Dis 46(1):166\u2013177. https:\/\/doi.org\/10.1007\/s12639-021-01431-9","journal-title":"J Parasit Dis"},{"issue":"1","key":"8280_CR4","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.sjbs.2020.11.007","volume":"28","author":"ES Al-Malki","year":"2021","unstructured":"Al-Malki ES (2021) Toxoplasmosis: stages of the protozoan life cycle and risk assessment in humans and animals for an enhanced awareness and an improved socio-economic status. Saudi J Biol Sci 28(1):962\u2013969","journal-title":"Saudi J Biol Sci"},{"issue":"11","key":"8280_CR5","doi-asserted-by":"publisher","first-page":"e00189","DOI":"10.1016\/j.parepi.2020.e00189","volume":"21","author":"K Cheraghipour","year":"2020","unstructured":"Cheraghipour K, Masoori L, Ezzatkhah F, Salimikia I, Amiri S, Makenali AS, Taherpour F, Mahmoudvand H (2020) Effect of chitosan on Toxoplasma gondii infection: a systematic review. Parasite Epidemiol Control 21(11):e00189. https:\/\/doi.org\/10.1016\/j.parepi.2020.e00189","journal-title":"Parasite Epidemiol Control"},{"issue":"4","key":"8280_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.vetpar.2005.06.007","volume":"133","author":"JP Dubey","year":"2005","unstructured":"Dubey JP (2005) Unexpected oocyst shedding by cats fed Toxoplasma gondii tachyzoites: in vivo stage conversion and strain variation. Vet Parasitol 133(4):289\u201398. https:\/\/doi.org\/10.1016\/j.vetpar.2005.06.007","journal-title":"Vet Parasitol"},{"key":"8280_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2217\/fmb-2016-0146","volume":"12","author":"C Ducournau","year":"2017","unstructured":"Ducournau C, Nguyen TT, Carpentier R, Lantier I, Germon S, Pr\u00e9causta F, Pisella PJ, Leroux H, Van Langendonck N, Betbeder D, Dimier-Poisson I (2017) Synthetic parasites: a successful mucosal nanoparticle vaccine against Toxoplasma congenital infection in mice. Future Microbiol 12:393\u2013405. https:\/\/doi.org\/10.2217\/fmb-2016-0146","journal-title":"Future Microbiol"},{"issue":"11","key":"8280_CR8","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3389\/fimmu.2020.02183","volume":"9","author":"C Ducournau","year":"2020","unstructured":"Ducournau C, Moir\u00e9 N, Carpentier R, Cantin P, Herkt C, Lantier I, Betbeder D, Dimier-Poisson I (2020) Effective nanoparticle-based nasal vaccine against latent and congenital toxoplasmosis in sheep. Front Immunol 9(11):2183. https:\/\/doi.org\/10.3389\/fimmu.2020.02183","journal-title":"Front Immunol"},{"key":"8280_CR9","doi-asserted-by":"publisher","first-page":"106810","DOI":"10.1016\/j.actatropica.2022.106810","volume":"239","author":"BM El Sharazly","year":"2023","unstructured":"El Sharazly BM, Aboul Asaad IA, Yassen NA, El Maghraby GM, Carter WG, Mohamed DA, Amer BS, Ismail HIH (2023) Mefloquine loaded niosomes as a promising approach for the treatment of acute and chronic toxoplasmosis. Acta Trop 239:106810. https:\/\/doi.org\/10.1016\/j.actatropica.2022.106810","journal-title":"Acta Trop"},{"issue":"1","key":"8280_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12639-017-0973-8","volume":"42","author":"SE Etewa","year":"2018","unstructured":"Etewa SE, El-Maaty DAA, Hamza RS, Metwaly AS, Sarhan MH, Abdel-Rahman SA, Fathy GM, El-Shafey MA (2018) Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice. J Parasit Dis 42(1):102\u2013113. https:\/\/doi.org\/10.1007\/s12639-017-0973-8","journal-title":"J Parasit Dis"},{"issue":"4","key":"8280_CR11","doi-asserted-by":"publisher","first-page":"e0250079","DOI":"10.1371\/journal.pone.0250079","volume":"16","author":"FF Evangelista","year":"2021","unstructured":"Evangelista FF, Costa-Ferreira W, Mantelo FM, Beletini LF, de Souza AH, de Laet Sant\u2019Ana P, de Lima KK, Crestani CC, Falavigna-Guilherme AL (2021) Rosuvastatin revert memory impairment and anxiogenic-like effect in mice infected with the chronic ME-49 strain of Toxoplasma gondii. PLoS One 16(4):e0250079. https:\/\/doi.org\/10.1371\/journal.pone.0250079","journal-title":"PLoS One"},{"issue":"1","key":"8280_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00436-023-08038-4","volume":"123","author":"FF Evangelista","year":"2023","unstructured":"Evangelista FF, de Laet Sant\u2019Ana P, Ferreira WC, Ferreira TA, Dos Santos ML, de Souza AH, de Andrade FAL, da Silva DA, de Barros LD, Colli CM, Nogueira-Melo GA, Costa IN, Falavigna-Guilherme AL (2023) The Brazilian Toxoplasma gondii strain BRI caused greater inflammation and impairment in anxiogenic behavior in mice, which was reverted by rosuvastatin treatment. Parasitol Res. 123(1):64. https:\/\/doi.org\/10.1007\/s00436-023-08038-4","journal-title":"Parasitol Res."},{"issue":"22","key":"8280_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijppaw.2023.09.002","volume":"7","author":"F Fasquelle","year":"2023","unstructured":"Fasquelle F, Scuotto A, Vreulx AC, Petit T, Charpentier T, Betbeder D (2023) Nasal vaccination of six squirrel monkeys (Saimiri sciureus): improved immunization protocol against Toxoplasma gondii with a nanoparticle-born vaccine. Int J Parasitol Parasites Wildl 7(22):69\u201374. https:\/\/doi.org\/10.1016\/j.ijppaw.2023.09.002","journal-title":"Int J Parasitol Parasites Wildl"},{"key":"8280_CR14","doi-asserted-by":"publisher","first-page":"107717","DOI":"10.1016\/j.exppara.2019.107717","volume":"204","author":"NA Hagras","year":"2019","unstructured":"Hagras NA, Allam AF, Farag HF, Osman MM, Shalaby TI, Fawzy Hussein Mogahed NM, Tolba MM, Shehab AY (2019) Successful treatment of acute experimental toxoplasmosis by spiramycin-loaded chitosan nanoparticles. Exp Parasitol 204:107717. https:\/\/doi.org\/10.1016\/j.exppara.2019.107717","journal-title":"Exp Parasitol"},{"issue":"3","key":"8280_CR15","doi-asserted-by":"publisher","first-page":"e0010268","DOI":"10.1371\/journal.pntd.0010268","volume":"16","author":"NA Hagras","year":"2022","unstructured":"Hagras NA, Mogahed NM, Sheta E, Darwish AA, El-hawary MA, Hamed MT, Elwakil BH (2022) The powerful synergistic effect of spiramycin\/propolis loaded chitosan\/alginate nanoparticles on acute murine toxoplasmosis. PLoS Negl Trop Dis 16(3):e0010268. https:\/\/doi.org\/10.1371\/journal.pntd.0010268","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"8280_CR16","first-page":"138","volume":"10","author":"HK Hamad","year":"2018","unstructured":"Hamad HK, Ramadan NF, Mohamed SH, Aly I, Zalat R (2018) Parasitological and immunological study of the effect of chitosan and chitosan nanoparticles loaded with spiramycin on toxoplasmosis. J Global Pharm Technol 10(6):138\u2013145","journal-title":"J Global Pharm Technol"},{"key":"8280_CR17","doi-asserted-by":"publisher","unstructured":"Hamad HK, Ramadan NF, Mohamed SH, Aly I, Zalat R (2020) Study the synergistic effect between nanoparticles and Spiramycin on immunological response against Toxoplasmosis. IOP Conf. Series 736:022091. IOP Publishing. https:\/\/doi.org\/10.1088\/1757-899X\/736\/2\/02209","DOI":"10.1088\/1757-899X\/736\/2\/02209"},{"issue":"1","key":"8280_CR18","doi-asserted-by":"publisher","first-page":"9509","DOI":"10.1038\/s41598-021-89031-8","volume":"11","author":"K Hatam-Nahavandi","year":"2021","unstructured":"Hatam-Nahavandi K, Calero-Bernal R, Rahimi MT, Pagheh AS, Zarean M, Dezhkam A, Ahmadpour E (2021) Toxoplasma gondii infection in domestic and wild felids as public health concerns: a systematic review and meta-analysis. Sci Rep 11(1):9509. https:\/\/doi.org\/10.1038\/s41598-021-89031-8","journal-title":"Sci Rep"},{"key":"8280_CR19","doi-asserted-by":"publisher","unstructured":"Ismael SS (2023) Role of nanotechnology in treating of Toxoplasma gondii. In: Abbas RZ, Hassan MF, Khan A, Mohsin M (eds) Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan,  2:202\u2013212. https:\/\/doi.org\/10.47278\/book.zoon\/2023.64","DOI":"10.47278\/book.zoon\/2023.64"},{"issue":"1","key":"8280_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2174\/1574891X15666200604115001","volume":"15","author":"A Keyhani","year":"2020","unstructured":"Keyhani A, Shakibaie M, Mahmoudvand H, Jahanbakhsh S, Kareshk AT, Shojaee S, Ziaali N (2020) Prophylactic activity of biogenic selenium nanoparticles against chronic Toxoplasma gondii infection. Recent Pat Antiinfect Drug Discov 15(1):75\u201384. https:\/\/doi.org\/10.2174\/1574891X15666200604115001","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"8280_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1186\/s13071-020-04441-3","volume":"13","author":"L Manuel","year":"2020","unstructured":"Manuel L, Santos-Gomes G, Noormahomed EV (2020) Human toxoplasmosis in Mozambique: gaps in knowledge and research opportunities. Parasites Vectors 13:571. https:\/\/doi.org\/10.1186\/s13071-020-04441-3","journal-title":"Parasites Vectors"},{"issue":"7","key":"8280_CR22","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1586\/eri.12.58","volume":"10","author":"PA Moncada","year":"2012","unstructured":"Moncada PA, Montoya JG (2012) Toxoplasmosis in the fetus and newborn: an update on prevalence, diagnosis and treatment. Expert Rev Anti Infect Ther 10(7):815\u2013828. https:\/\/doi.org\/10.1586\/eri.12.58","journal-title":"Expert Rev Anti Infect Ther"},{"key":"8280_CR23","doi-asserted-by":"publisher","first-page":"7135268","DOI":"10.1155\/2020\/7135268","volume":"6","author":"JM Mose","year":"2020","unstructured":"Mose JM, Kagira JM, Kamau DM, Maina NW, Ngotho M, Karanja SM (2020) A review on the present advances on studies of Toxoplasmosis in Eastern Africa. Biomed Res Int 6:7135268. https:\/\/doi.org\/10.1155\/2020\/7135268","journal-title":"Biomed Res Int"},{"issue":"10","key":"8280_CR24","doi-asserted-by":"publisher","first-page":"e69182","DOI":"10.7554\/eLife.69182","volume":"8","author":"GC Olivera","year":"2021","unstructured":"Olivera GC, Ross EC, Peuckert C, Barragan A (2021) Blood-brain barrier-restricted translocation of Toxoplasma gondii from cortical capillaries. Elife 8(10):e69182. https:\/\/doi.org\/10.7554\/eLife.69182","journal-title":"Elife"},{"issue":"3","key":"8280_CR25","doi-asserted-by":"publisher","first-page":"941","DOI":"10.21608\/BMFJ.2022.116115.1529","volume":"39","author":"SM Rashed","year":"2022","unstructured":"Rashed SM, Abououf EA, Hassan MA, Barakat EM, Sadek SA, Ahmed FA, Ali HS (2022) Effect of ciprofloxacin loaded on silver nanoparticles on acute toxoplasmosis. BMFJ 39(3):941\u2013953. https:\/\/doi.org\/10.21608\/BMFJ.2022.116115.1529","journal-title":"BMFJ"},{"key":"8280_CR26","doi-asserted-by":"publisher","unstructured":"Ribeiro CM, Zorgi NE, Meireles LR, Garcia JL, Andrade HF Jr (2016) CD19 lymphocyte proliferation induced by Bifidobacterium animalis subsp. lactis in C57BL\/6 mice experimentally infected with Toxoplasma gondii. Rev Inst Med Trop Sao Paulo 58:26. https:\/\/doi.org\/10.1590\/S1678-9946201658026","DOI":"10.1590\/S1678-9946201658026"},{"issue":"4","key":"8280_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2144\/btn-2022-0005","volume":"72","author":"JP Robinson","year":"2022","unstructured":"Robinson JP (2022) Flow cytometry: past and future. Biotechniques 72(4):159\u2013169. https:\/\/doi.org\/10.2144\/btn-2022-0005","journal-title":"Biotechniques"},{"key":"8280_CR28","doi-asserted-by":"publisher","first-page":"106830","DOI":"10.1016\/j.actatropica.2023.106830","volume":"239","author":"AE Saad","year":"2023","unstructured":"Saad AE, Zoghroban HS, Ghanem HB, El-Guindy DM, Younis SS (2023) The effects of L-citrulline adjunctive treatment of Toxoplasma gondii RH strain infection in a mouse model. Acta Trop 239:106830. https:\/\/doi.org\/10.1016\/j.actatropica.2023.106830","journal-title":"Acta Trop"},{"issue":"1","key":"8280_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/ph17010113","volume":"17","author":"MH Sarhan","year":"2024","unstructured":"Sarhan MH, Felemban SG, Alelwani W, Sharaf HM, Abd El-Latif YA, Elgazzar E, Kandil AM, Tellez-Isaias G, Mohamed AA (2024) Zinc oxide and magnesium-doped zinc oxide nanoparticles ameliorate murine chronic toxoplasmosis. Pharmaceuticals 17(1):113. https:\/\/doi.org\/10.3390\/ph17010113","journal-title":"Pharmaceuticals"},{"key":"8280_CR30","doi-asserted-by":"publisher","first-page":"7743","DOI":"10.2147\/IDR.S443047","volume":"16","author":"MH Wakid","year":"2023","unstructured":"Wakid MH, Alsulami MN, Farid M, El Kholy WA (2023) Potential anti-toxoplasmosis efficiency of Phoenix dactylifera extracts loaded on selenium nanoparticles. Infect Drug Resist 16:7743\u20137758. https:\/\/doi.org\/10.2147\/IDR.S443047","journal-title":"Infect Drug Resist"},{"issue":"2022","key":"8280_CR31","doi-asserted-by":"publisher","first-page":"2165205","DOI":"10.1155\/2022\/2165205","volume":"16","author":"SH Yahia","year":"2022","unstructured":"Yahia SH, Etewa SE, Saleh NS, Mohammad SM, Aboulfotouh NI, Kandil AM, Sarhan MH (2022) Histopathological, immunohistochemical and biochemical studies of murine hepatosplenic tissues affected by chronic toxoplasmosis. J Parasitol Res 16(2022):2165205. https:\/\/doi.org\/10.1155\/2022\/2165205","journal-title":"J Parasitol Res"}],"container-title":["Parasitology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-024-08280-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00436-024-08280-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-024-08280-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T04:09:36Z","timestamp":1722658176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00436-024-08280-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["8280"],"URL":"https:\/\/doi.org\/10.1007\/s00436-024-08280-4","relation":{},"ISSN":["0932-0113","1432-1955"],"issn-type":[{"value":"0932-0113","type":"print"},{"value":"1432-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the Research and Ethics Committee of the National Liver Institute, Menoufia University. The study complies with the NLI Institutional Review Board (IRB) protocol number 00003413.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical consideration"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"286"}}